Why T6 is the watershed level
Neurogenic shock is a distributive shock caused by loss of sympathetic vasomotor tone after spinal cord injury (SCI). The sympathetic preganglionic neurons that control vascular tone and heart rate exit the spinal cord from
T1 through
L2, with the most clinically important cardioaccelerator and vasoconstrictor outflow concentrated in the upper thoracic segments. When the cord is injured
at or above approximately the sixth thoracic level (T6), the descending sympathetic pathways are sufficiently interrupted to produce widespread vasodilation, venous pooling, and unopposed vagal activity, resulting in the classic triad of hypotension, bradycardia, and warm dry skin seen in Client 3
[1][4].
Key point! The sympathetic chain receives supraspinal input that descends through the cord. An injury below T6 leaves enough sympathetic outflow intact to maintain vascular tone in most of the body, so neurogenic shock is uncommon with lower thoracic or lumbar injuries
[3][4].
Anatomical basis of the T6 threshold
Sympathetic fibers to the heart arise from
T1–T4, while splanchnic vasomotor control—responsible for a large portion of total peripheral resistance—originates from
T5–T9. An injury at T6 or above disrupts both cardiac sympathetic drive and splanchnic vasoconstriction. The result is a functional sympathectomy: blood vessels dilate, systemic vascular resistance falls, and the baroreceptor reflex cannot mount a compensatory tachycardia because vagal tone is unopposed
[1][3]. This explains Client 3’s
heart rate of 50/min and
blood pressure of 80/46 mmHg.
Watch out! Bradycardia is a hallmark that distinguishes neurogenic shock from hypovolemic or septic shock, where tachycardia is the expected compensatory response. The warm, dry skin also contrasts with the cool, clammy skin of hypovolemic shock because vasodilation, not vasoconstriction, dominates
[1].
Why the other levels are incorrect
| Injury level | Effect on sympathetic outflow | Neurogenic shock expected? |
|---|
| C1–C4 only | Complete loss of all sympathetic and parasympathetic control; often fatal respiratory failure | Yes, but neurogenic shock is not limited to this range |
| T6 or above | Interrupts cardiac (T1–T4) and splanchnic (T5–T9) sympathetic outflow | Yes—this is the defining threshold |
| T12 or below | Most sympathetic outflow remains intact; only lower extremity and pelvic vasomotor control lost | No—hypotension is not typically neurogenic in origin |
| L1 or below | Below the sympathetic preganglionic outflow (T1–L2), minimal vasomotor impact | No—neurogenic shock is not expected |
Clinical application for the emergency department
The initial priority for Client 3 is stabilization using the ABCDE approach, with spinal immobilization maintained throughout. Because neurogenic shock reflects loss of vascular tone rather than volume loss, fluid resuscitation alone is often insufficient. Vasopressor support—typically an alpha-agonist such as norepinephrine or phenylephrine—is used to restore vasomotor tone and maintain a
mean arterial pressure (MAP) above
85–90 mmHg to preserve spinal cord perfusion and reduce secondary ischemic injury
[4]. Continuous hemodynamic monitoring is essential because the loss of sympathetic compensation makes these clients exquisitely sensitive to position changes and positive pressure ventilation
[1].
Key point! The level of injury predicts the hemodynamic pattern. A client with a cervical or high thoracic injury who presents with hypotension and bradycardia should be assumed to have neurogenic shock until proven otherwise, and vasopressor therapy should be initiated early rather than waiting for fluid resuscitation to fail
[4].
References (research sources)
- [1]
[Neurogenic shock].Research articleMeister R, Pasquier M, Clerc D, Carron PN (2014)
- [3]
Vascular dysfunctions following spinal cord injury.Research articlePopa C, Popa F, Grigorean VT, Onose G, Sandu AM, Popescu M (2010)
- [4]
Contemporary hemodynamic management of acute spinal cord injuries with intravenous and enteral vasoactive agents: A narrative review.Research articleIovine JA, Villanueva RD, Werth CM, Hlavacek NL, Rollstin AD, Tawil I (2022) · DOI: 10.1093/ajhp/zxac164